Processa pharmaceuticals provides update on enrollment across all clinical programs

Hanover, md, sept. 15, 2022 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa), (“processa” or “company”), a clinical stage biopharmaceutical company focused on developing products to improve survival and/or quality of life for patients who have an unmet medical need condition for which there are few or no therapeutic options, today provided an update on enrollment across all its clinical programs.
PCSA Ratings Summary
PCSA Quant Ranking